David M. Stack Joins Board of Directors of Molecular Insight Pharmaceuticals, Inc.
Cambridge, MA, April 12, 2006 – Molecular Insight Pharmaceuticals, Inc. today announced that David M. Stack has joined the company's Board of Directors. Mr. Stack brings over 25 years of experience in marketing, sales and commercialization at companies in the biotechnology and pharmaceutical sectors, including Roche Labs, Innovex, The Medicines Company and MPM Capital.
Mr. Stack is currently Executive Partner at MPM Capital's MPM BioVentures IV Fund. Previously, he served as President and Chief Executive Officer of The Medicines Company, which specializes in acute care pharmaceuticals. Prior to The Medicines Company, he served as President of Innovex Inc. Previously, Mr. Stack served as Vice President of Business Development at Immunomedics, and before that he held a variety of positions of increasing responsibility at Roche Laboratories, most recently as Director, Business Development and Planning, Infectious Disease, Oncology, and Virology. Mr. Stack holds a B.S. degree in Biology from Siena College and a B.S. degree in Pharmacy from the Albany College of Pharmacy.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics. The company's product candidates target markets with significant unmet needs in cardiology, oncology, and neurology. Molecular Insight's lead product candidate, Zemiva™ (iodofiltic acid I 123) is in development as a molecular imaging pharmaceutical for the diagnosis of insufficient blood flow to the heart, or cardiac ischemia. The company's second lead product candidate, Azedra™ (Ultratrace™ MIBG), is in development for the diagnosis and treatment of neuroendocrine tumors. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts. The company’s website is: www.molecularinsight.com.
Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554